Literature DB >> 9568031

Antibodies directed to envelope proteins of hepatitis C virus outside of hypervariable region 1.

S Lechner1, K Rispeter, H Meisel, W Kraas, G Jung, M Roggendorf, A Zibert.   

Abstract

The relatively high variability of the hepatitis C virus (HCV) envelope proteins E1 and E2 suggests that parts of these proteins other than the hypervariable region 1 (HVR1) might be involved in the induction of virus neutralizing antibodies. To test this hypothesis, two HCV proteins, pE1 and pE2 delta, were generated by in vitro translation. They represent amino acids 174-337 of E1 and 411-688 of E2, respectively, of isolate HCV-AD78; the protein pE2 delta contained no HVR1. As a control, protein pG.HVR1, which represents amino acids 384-410 of HVR1 of isolate HCV-AD78, was expressed separately. These three proteins were used in an immunoprecipitation assay to detect the presence of antiviral antibodies in sera of patients infected with the same isolate of HCV (HCV-AD78). Sera were obtained 4-8 months postinfection from patients who later resolved an acute infection or developed chronic liver disease. A high prevalence of antibodies (up to 85.7%) against pE1 and pE2 delta could be detected in both groups of patients, suggesting that these forms of the HCV envelope proteins contain B-cell epitopes. The antibody responses against proteins pE1 and pE2 delta did not differ significantly between patients with resolving or chronic infection, whereas antibodies against protein pG.HVR1 were associated with resolution of infection. Rabbit antisera raised against pE1 and pE2 delta were tested for their ability to neutralize the binding of HCV to susceptible cells in tissue cultures. The results suggested that although a few B-cell epitopes outside of HVR1 can induce virus neutralizing antibodies, these antibodies are probably not associated with the resolution of infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9568031     DOI: 10.1006/viro.1998.9069

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

Review 1.  Immunopathogenesis of viral hepatitis.

Authors:  M U Mondelli
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

2.  Significance of pretreatment analysis of hepatitis C virus genotype 1b hypervariable region 1 sequences to predict antiviral outcome.

Authors:  Catherine Gaudy; Alain Moreau; Pascal Veillon; Stephanie Temoin; Francoise Lunel; Alain Goudeau
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

3.  Vaccination with dendritic cells pulsed with hepatitis C pseudo particles induces specific immune responses in mice.

Authors:  Kilian Weigand; Franziska Voigt; Jens Encke; Birgit Hoyler; Wolfgang Stremmel; Christoph Eisenbach
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

4.  Expression of hepatitis C virus hypervariable region 1 and its clinical significance.

Authors:  Xin-Xin Zhang; Shen-Ying Zhang; Jing Liu; Zhi-Meng Lu; Yuan Wang
Journal:  World J Gastroenterol       Date:  2003-05       Impact factor: 5.742

5.  A candidate DNA vaccine elicits HCV specific humoral and cellular immune responses.

Authors:  Li-Xin Zhu; Jing Liu; Ye Ye; You-Hua Xie; Yu-Ying Kong; Guang-Di Li; Yuan Wang
Journal:  World J Gastroenterol       Date:  2004-09-01       Impact factor: 5.742

6.  Cross-reactivity of hypervariable region 1 chimera of hepatitis C virus.

Authors:  Bing-Shui Xiu; Shi-Gan Ling; Xiao-Guo Song; He-Qiu Zhang; Kun Chen; Cui-Xia Zhu
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

Review 7.  Development of Preventive Vaccines for Hepatitis C Virus E1/E2 Protein.

Authors:  Faezeh Ghasemi; Majid Ghayour-Mobarhan; Hamed Gouklani; Zahra Meshkat
Journal:  Iran J Pathol       Date:  2018-07-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.